LAVA Provides Business Updates and Reports Fourth Quarter and Year-End Financial ResultsGlobeNewsWire • 03/20/24
LAVA Announces Clinical Development Milestone Achieved by Pfizer for PF-08046052 (formerly SGN-EGFRd2/LAVA-1223)GlobeNewsWire • 03/05/24
LAVA Therapeutics Announces Collaboration with Merck & Co., Inc., Rahway, NJ, USA to Evaluate LAVA-1207 in Combination with KEYTRUDA®GlobeNewsWire • 01/25/24
Lava Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial ResultsGlobeNewsWire • 11/16/23
LAVA Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment ConferenceGlobeNewsWire • 09/06/23
LAVA Therapeutics N.V. (LVTX) Reports Q2 Loss, Tops Revenue EstimatesZacks Investment Research • 08/22/23
LAVA Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial ResultsGlobeNewsWire • 08/22/23
LAVA Therapeutics to Participate in the H.C. Wainwright Immune Cell Engager Virtual ConferenceGlobeNewsWire • 08/14/23
LAVA Therapeutics Provides Updates on Clinical Programs and Extends the Cash RunwayGlobeNewsWire • 06/14/23
LAVA Therapeutics Provides Business Update and Reports First Quarter 2023 Financial ResultsGlobeNewsWire • 06/08/23
LAVA Therapeutics Announces Selection by Janssen of Lead Gamma-Delta T-Cell Engager Bispecific Antibody to Move Toward Clinical DevelopmentGlobeNewsWire • 06/01/23
LAVA Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2022 Financial ResultsGlobeNewsWire • 04/11/23
LAVA Therapeutics Announces Appointment of Christy J. Oliger to its Board of DirectorsGlobeNewsWire • 03/09/23
LAVA Therapeutics Announces Initial Data from the Ongoing Phase 1/2a Clinical Trial of LAVA-1207 in Therapy Refractory mCRPC at the 2023 ASCO GU SymposiumGlobeNewsWire • 02/16/23
LAVA Therapeutics to Present at the 2023 SVB Securities Global Biopharma ConferenceGlobeNewsWire • 02/09/23
LAVA Therapeutics Announces the Appointment of Dr. Charles Morris as Chief Medical OfficerGlobeNewsWire • 02/06/23
LAVA Therapeutics to Present LAVA-1207 Clinical Data at the 2023 ASCO GU SymposiumGlobeNewsWire • 01/23/23
LAVA Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/03/23
LAVA Therapeutics Announces Updated Data from the Phase 1/2a Clinical Trial of LAVA-051 at the 64th American Society of Hematology (ASH) Annual Meeting and ExpositionGlobeNewsWire • 12/10/22
Can LAVA Therapeutics N.V. (LVTX) Climb 198% to Reach the Level Wall Street Analysts Expect?Zacks Investment Research • 11/25/22